SRPT logo

Sarepta Therapeutics (SRPT) Cash and cash equivalents

annual cash & cash equivalents:

$1.10B+$674.58M(+157.45%)
December 31, 2024

Summary

  • As of today (June 1, 2025), SRPT annual cash & cash equivalents is $1.10 billion, with the most recent change of +$674.58 million (+157.45%) on December 31, 2024.
  • During the last 3 years, SRPT annual cash & cash equivalents has fallen by -$1.01 billion (-47.87%).
  • SRPT annual cash & cash equivalents is now -47.87% below its all-time high of $2.12 billion, reached on December 31, 2021.

Performance

SRPT Cash and cash equivalents Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherSRPTbalance sheet metrics

quarterly cash & cash equivalents:

$240.87M-$862.14M(-78.16%)
March 1, 2025

Summary

  • As of today (June 1, 2025), SRPT quarterly cash & cash equivalents is $240.87 million, with the most recent change of -$862.14 million (-78.16%) on March 1, 2025.
  • Over the past year, SRPT quarterly cash & cash equivalents has dropped by -$186.42 million (-43.63%).
  • SRPT quarterly cash & cash equivalents is now -88.62% below its all-time high of $2.12 billion, reached on December 31, 2021.

Performance

SRPT quarterly cash & cash equivalents Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherSRPTbalance sheet metrics

Cash and cash equivalents Formula

Cash & Cash Equivalents = Cash + Short-Term Investments

SRPT Cash and cash equivalents Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year+157.4%-43.6%
3 y3 years-47.9%-80.5%
5 y5 years+32.1%-86.3%

SRPT Cash and cash equivalents Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-year-47.9%+157.4%-80.5%+21.7%
5 y5-year-47.9%+157.4%-88.6%+21.7%
alltimeall time-47.9%>+9999.0%-88.6%>+9999.0%

SRPT Cash and cash equivalents History

DateAnnualQuarterly
Mar 2025
-
$240.87M(-78.2%)
Dec 2024
$1.10B(+157.5%)
$1.10B(+457.5%)
Sep 2024
-
$197.85M(-48.4%)
Jun 2024
-
$383.62M(-10.2%)
Mar 2024
-
$427.29M(-0.3%)
Dec 2023
$428.43M(-55.7%)
$428.43M(-20.9%)
Sep 2023
-
$541.93M(-36.4%)
Jun 2023
-
$851.93M(-2.3%)
Mar 2023
-
$871.67M(-9.8%)
Dec 2022
$966.78M(-54.3%)
$966.78M(-6.9%)
Sep 2022
-
$1.04B(+19.6%)
Jun 2022
-
$868.57M(-29.6%)
Mar 2022
-
$1.23B(-41.7%)
Dec 2021
$2.12B(+40.8%)
$2.12B(+32.3%)
Sep 2021
-
$1.60B(-5.8%)
Jun 2021
-
$1.70B(+14.5%)
Mar 2021
-
$1.48B(-1.4%)
Dec 2020
$1.50B(+79.9%)
$1.50B(+1.9%)
Sep 2020
-
$1.47B(-10.1%)
Jun 2020
-
$1.64B(-7.0%)
Mar 2020
-
$1.76B(+111.3%)
Dec 2019
$835.08M(+125.2%)
$835.08M(+15.2%)
Sep 2019
-
$724.83M(-10.4%)
Jun 2019
-
$808.59M(+10.4%)
Mar 2019
-
$732.19M(+97.4%)
Dec 2018
$370.83M(-38.2%)
$370.83M(+76.8%)
Sep 2018
-
$209.70M(-48.9%)
Jun 2018
-
$410.38M(-26.4%)
Mar 2018
-
$557.23M(-7.1%)
Dec 2017
$599.69M(+389.9%)
$599.69M(-2.9%)
Sep 2017
-
$617.63M(+266.9%)
Jun 2017
-
$168.35M(-38.7%)
Mar 2017
-
$274.72M(+124.4%)
Dec 2016
$122.42M(+52.4%)
$122.42M(-69.0%)
Sep 2016
-
$395.14M(+253.4%)
Jun 2016
-
$111.82M(+194.3%)
Mar 2016
-
$38.00M(-52.7%)
Dec 2015
$80.30M(+9.2%)
$80.30M(+43.9%)
Sep 2015
-
$55.82M(-19.7%)
Jun 2015
-
$69.54M(-6.6%)
Mar 2015
-
$74.44M(+1.2%)
Dec 2014
$73.55M(-71.4%)
$73.55M(+40.6%)
Sep 2014
-
$52.30M(-49.1%)
Jun 2014
-
$102.75M(+109.3%)
Mar 2014
-
$49.10M(-80.9%)
Dec 2013
$256.96M(+36.9%)
$256.96M(-6.1%)
Sep 2013
-
$273.64M(+75.2%)
Jun 2013
-
$156.19M(-7.0%)
Mar 2013
-
$167.92M(-10.5%)
Dec 2012
$187.66M(+370.3%)
$187.66M(+394.0%)
Sep 2012
-
$37.99M(+55.1%)
Jun 2012
-
$24.49M(-19.9%)
Mar 2012
-
$30.57M(-23.4%)
Dec 2011
$39.90M(+18.8%)
$39.90M(-13.9%)
Sep 2011
-
$46.36M(-14.5%)
Jun 2011
-
$54.19M(+132.7%)
Mar 2011
-
$23.28M(-30.7%)
DateAnnualQuarterly
Dec 2010
$33.59M(-30.4%)
$33.59M(-6.6%)
Sep 2010
-
$35.97M(-2.1%)
Jun 2010
-
$36.74M(-11.3%)
Mar 2010
-
$41.44M(-14.2%)
Dec 2009
$48.27M(+331.3%)
$48.27M(-4.0%)
Sep 2009
-
$50.27M(+150.9%)
Jun 2009
-
$20.04M(-19.0%)
Mar 2009
-
$24.72M(+120.9%)
Dec 2008
$11.19M(-54.9%)
$11.19M(-20.5%)
Sep 2008
-
$14.08M(-23.9%)
Jun 2008
-
$18.51M(-7.3%)
Mar 2008
-
$19.96M(-19.5%)
Dec 2007
$24.80M(+23.0%)
$24.80M(+542.3%)
Sep 2007
-
$3.86M(-58.3%)
Jun 2007
-
$9.26M(-38.1%)
Mar 2007
-
$14.96M(-25.8%)
Dec 2006
$20.16M(-41.7%)
$20.16M(-21.2%)
Sep 2006
-
$25.58M(-19.5%)
Jun 2006
-
$31.76M(-13.8%)
Mar 2006
-
$36.87M(+6.6%)
Dec 2005
$34.60M(+107.7%)
$34.60M(+25.6%)
Sep 2005
-
$27.56M(+0.8%)
Jun 2005
-
$27.35M(-20.4%)
Mar 2005
-
$34.36M(+106.3%)
Dec 2004
$16.65M(+33.0%)
$16.65M(+34.9%)
Sep 2004
-
$12.34M(+11.7%)
Jun 2004
-
$11.04M(+27.1%)
Mar 2004
-
$8.69M(-30.6%)
Dec 2003
$12.52M(+20.6%)
$12.52M(+91.8%)
Sep 2003
-
$6.53M(-28.1%)
Jun 2003
-
$9.08M(+26.6%)
Mar 2003
-
$7.17M(-30.9%)
Dec 2002
$10.38M(-6.2%)
$10.38M(-17.5%)
Sep 2002
-
$12.59M(-6.4%)
Jun 2002
-
$13.45M(-55.0%)
Mar 2002
-
$29.89M(+170.0%)
Dec 2001
$11.07M(-57.3%)
$11.07M(-55.0%)
Sep 2001
-
$24.61M(-12.5%)
Jun 2001
-
$28.13M(+27.9%)
Mar 2001
-
$22.00M(-15.0%)
Dec 2000
$25.90M(+197.7%)
$25.90M(-12.4%)
Sep 2000
-
$29.55M(+325.3%)
Jun 2000
-
$6.95M(-27.5%)
Mar 2000
-
$9.58M(+10.1%)
Dec 1999
$8.70M(+2.4%)
$8.70M(+262.5%)
Sep 1999
-
$2.40M(-45.5%)
Jun 1999
-
$4.40M(-34.3%)
Mar 1999
-
$6.70M(-21.2%)
Dec 1998
$8.50M(-51.7%)
$8.50M(-22.0%)
Sep 1998
-
$10.90M(-17.4%)
Jun 1998
-
$13.20M(-16.5%)
Mar 1998
-
$15.80M(-10.2%)
Dec 1997
$17.60M(+486.7%)
$17.60M(-4.9%)
Sep 1997
-
$18.50M(+5.1%)
Jun 1997
-
$17.60M(+665.2%)
Mar 1997
-
$2.30M
Dec 1996
$3.00M
-

FAQ

  • What is Sarepta Therapeutics annual cash & cash equivalents?
  • What is the all time high annual cash & cash equivalents for Sarepta Therapeutics?
  • What is Sarepta Therapeutics annual cash & cash equivalents year-on-year change?
  • What is Sarepta Therapeutics quarterly cash & cash equivalents?
  • What is the all time high quarterly cash & cash equivalents for Sarepta Therapeutics?
  • What is Sarepta Therapeutics quarterly cash & cash equivalents year-on-year change?

What is Sarepta Therapeutics annual cash & cash equivalents?

The current annual cash & cash equivalents of SRPT is $1.10B

What is the all time high annual cash & cash equivalents for Sarepta Therapeutics?

Sarepta Therapeutics all-time high annual cash & cash equivalents is $2.12B

What is Sarepta Therapeutics annual cash & cash equivalents year-on-year change?

Over the past year, SRPT annual cash & cash equivalents has changed by +$674.58M (+157.45%)

What is Sarepta Therapeutics quarterly cash & cash equivalents?

The current quarterly cash & cash equivalents of SRPT is $240.87M

What is the all time high quarterly cash & cash equivalents for Sarepta Therapeutics?

Sarepta Therapeutics all-time high quarterly cash & cash equivalents is $2.12B

What is Sarepta Therapeutics quarterly cash & cash equivalents year-on-year change?

Over the past year, SRPT quarterly cash & cash equivalents has changed by -$186.42M (-43.63%)
On this page